Sharon Daily is the Director of the Global Health Impact Center where she directs a team of diverse multidisciplinary scientists and project managers. She has experience leading medical product development programs combining technical and managerial oversight. Currently, she is the Regulatory Core Lead for the National Heart, Lung, and Blood Institute (NHLBI)-funded Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies (CONNECTS) Coordinating Center and the Technical lead of the NHLBI-funded CATALYZE Translational Coordinating Center. She also supports the Combatting Antibiotic Resistance Bacteria Accelerator (CARB-X) project and Qura Therapeutics (HIV therapy) initiatives.
A board-certified toxicologist (Diplomate of American Board of Toxicology) by training, Dr. Daily has more than 20 years of experience in the pharmaceutical industry specializing in regulatory strategy of nonclinical safety programs for drugs and biologics. She has planned, conducted, and monitored nonclinical studies in an array of animal models across multiple therapeutic areas. Drawing upon her extensive experience in biopharmaceutical product development, Dr. Daily helps teams understand the relevant U.S. Food and Drug Administration (FDA) guidances that are the backbone of successful regulatory submissions for clinical trials. She has expertise in the support of pre-Investigational New Drug applications (pINDs) and meetings, Investigational New Drug (IND) applications, New Drug Applications (NDAs), and additional related submissions to the FDA.
Prior to joining RTI in 2016, Dr. Daily worked at Aventis Pharmaceuticals, Sanofi, Cato Research, Paraxel International and GSK. She is also a part of the Society of Toxicology.
